A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Peginterferon Alfa-2A (Pegasys)

Interferon alpha class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2002-10-16
Generic availableNo (brand-only)
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$46.2M in CY2024 Part D spend12K claims · 2K beneficiaries · 329 plans surveyed

Lowest NADAC
$1070.90/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1070.90
Across all dosage forms in distribution.
Highest NADAC
$1070.90
Range is tight.
Plans with PA
464 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Peginterferon Alfa-2A used for?

Peginterferon Alfa-2A is a Interferon alpha medication tracked in Medicare Part D.

Is there a generic for Peginterferon Alfa-2A?

No. Peginterferon Alfa-2A is brand-only with no generic equivalents currently in market.

How much does my plan pay for Peginterferon Alfa-2A?

Across 329 Part D plans, Peginterferon Alfa-2A averages $1070.90/unit (NADAC). Lowest available: $1070.90/unit. Highest in distribution: $1070.90/unit.

Is Peginterferon Alfa-2A on the FDA shortage list?

Yes. Peginterferon Alfa-2A is currently listed as an active FDA shortage.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.